Overview

Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma

Status:
Recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
This is a single arm trial of participants with Merkel cell carcinoma receiving a combination of lenvatinib plus pembrolizumab.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Lenvatinib
Pembrolizumab